Zhang, Ruiqi
Mamza, Jil Billy
Morris, Tamsin
Godfrey, George
Asselbergs, Folkert W.
Denaxas, Spiros
Hemingway, Harry
Banerjee, Amitava http://orcid.org/0000-0001-8741-3411
Funding for this research was provided by:
AstraZeneca
Article History
Received: 27 August 2021
Accepted: 4 January 2022
First Online: 7 February 2022
Change Date: 23 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12916-022-02308-1
Declarations
:
: This study is based in part on data from the CPRD obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the NHS as part of their care and support. The ONS is also acknowledge as the provider of the ONS Data contained within the CPRD Data. The interpretation and conclusions contained in this study are those of the author/s alone. Copyright© (2020), re-used with the permission of NHS Digital. All rights reserved. The study protocol was approved by the Independent Scientific Advisory Committee (ISAC) of CPRD; protocol reference number: 19_115.
: Not applicable.
: AB is supported by research funding from NIHR, British Medical Association, AstraZeneca and UK Research and Innovation. HH is a National Institute for Health Research (NIHR) Senior Investigator. FA and HH are funded by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. HH work is supported by: 1. Health Data Research UK (grant No. LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust. AB, FA, SD and HH are part of the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA; it is chaired, by DE Grobbee and SD Anker, partnering with 20 academic and industry partners and ESC. RZ, JBM, GG and TM are employed by AstraZeneca UK Ltd, a biopharmaceutical company.